- Home
- ANVS vs CALC Comparison
ANVS vs CALC Comparison
Compare ANVS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- CALC
- Stock Information
- Founded
- ANVS 2008
- CALC 2011
- Country
- ANVS United States
- CALC United States
- Employees
- ANVS N/A
- CALC N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- CALC Health Care
- Exchange
- ANVS Nasdaq
- CALC Nasdaq
- Market Cap
- ANVS 55.5M
- CALC 48.1M
- IPO Year
- ANVS 2020
- CALC N/A
- Fundamental
- Price
- ANVS $2.34
- CALC $3.09
- Analyst Decision
- ANVS Strong Buy
- CALC Strong Buy
- Analyst Count
- ANVS 4
- CALC 2
- Target Price
- ANVS $17.33
- CALC $14.50
- AVG Volume (30 Days)
- ANVS 231.9K
- CALC 53.0K
- Earning Date
- ANVS 11-07-2025
- CALC 08-12-2025
- Dividend Yield
- ANVS N/A
- CALC N/A
- EPS Growth
- ANVS N/A
- CALC N/A
- EPS
- ANVS N/A
- CALC N/A
- Revenue
- ANVS N/A
- CALC N/A
- Revenue This Year
- ANVS N/A
- CALC N/A
- Revenue Next Year
- ANVS N/A
- CALC N/A
- P/E Ratio
- ANVS N/A
- CALC N/A
- Revenue Growth
- ANVS N/A
- CALC N/A
- 52 Week Low
- ANVS $1.11
- CALC $1.42
- 52 Week High
- ANVS $10.54
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- ANVS 43.00
- CALC 56.35
- Support Level
- ANVS $2.21
- CALC $3.04
- Resistance Level
- ANVS $2.51
- CALC $3.38
- Average True Range (ATR)
- ANVS 0.13
- CALC 0.24
- MACD
- ANVS -0.01
- CALC 0.02
- Stochastic Oscillator
- ANVS 25.35
- CALC 58.57
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.